Theratechnologies Inc T.TH

$84B global NASH market by 2029

[scarlet1967]

Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment - Oramed Pharmaceuticals

Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment - Oramed Pharmaceuticals

 

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials - Oramed Pharmaceuticals

“The global market for drugs to treat NASH is expected to reach $84 billion by 2029.”

 

This is one way to spread the news.

This company seems to be developing mostly oral drugs for diabetes type 1/2 and patients suffering from both diabetes and NASH. Looking through their PRs there were some mentioning of Covid Vaccin. The company and Premas Biotech created a new company Oravax (preclinical covid so far). In the past 12 months their valuation has appreciated by 670%.

Over 4000 followers on Stocktwits, valuation over $660M, over 800k daily volume.

Point is there are no norms re how to spread  the news. THTX has an open label cancer trial yet they don’t know anything about it’s progress as per the chat with Ed Nash?Their progresses with regulators for NASH seems to be handled by the secret service until now they are trying to bring it back to spot lights! Shares are currently“ridiculously cheap” for a good reason and the reason is…

[longterm56]

Does the statement "The global market for drugs to treat NASH is expected to reach $84 billion by 2029" mean ... a) in 2029 the annual sales will be $84B? b) between now and 2029 the cumulative sales will total $84B?  Thanks -     -LT quote=scarlet1967] Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment - Oramed Pharmaceuticals Oramed's

[SPCEO1]

It means annual sales in 2029 will be $84 billion. But that is just hype. The chances of t hat being an accurate statement are very, very low. [/quote]

[Wino115]

Global diabetes is around $60bil and N.Am is something like $25bil.  Total Hepatitis market is around $20bil I think.  So maybe it's something between those two globally. No one really knows pricing yet or what insurers will push toward. Given the fuzziness around clear testing, insureres will tamper down pricing expectations. [/quote]

[scarlet1967]

That reference was based on the report below from July 2020 (probably overestimated). I am not sure how factual the actual report is but they are including some valid factors in the description. This company (Oramed) seems to believe it’s an good idea to keep investors informed even if they have reached 25% enrolment for their trial maybe not common practice but obviously they want to create a